The Research and Development Day will feature a presentation by Key Opinion Leader (KOL) Michael Kalos, Ph.D. (Director of IMV, Inc.) who will discuss why IMV’s DPX platform represents a promising technology to address unmet medical needs in oncology.

The IMV team will describe the DPX delivery platform technology and its unique immune-educating capability, highlighting key advantages demonstrated in both clinical and translational data as well as its exceptional safety profile. The DPX platform is used to create unique immunotherapies in oncology that can be easily combined with other therapies.

IMV management will give an update on the Company’s clinical programs. A live question and answer session will follow.